He shares a short clip on why he started a GLP-1 and what it has been like, and points to a longer YouTube video that goes deeper.
Recap by typeshit. Post by @jeremyjacobowitz on Instagram.
CNBC's investing team lifts its target on Lilly shares and argues the obesity drug run still has room to grow.
The Pharma Letter looks at how semaglutide generics are changing strategy in India, with Torrent eyeing an expansion into Brazil.
Semafor looks at how little national political figures have said about what the new class of weight loss drugs means for policy.
The doctors take on two of the topics their followers ask about most, giving their verdict on statins and Ozempic.
A retail trade report maps out the points where grocers can connect with shoppers taking GLP-1 drugs.
People on GLP-1 drugs report fewer alcohol cravings, and KTSM says the drugs' popularity is now becoming a challenge for brewers.
Loading…